WASHINGTON and BOGOTA, Colombia, June 1, 2021 /PRNewswire/ — ACON Investments L.L.C. and its associates (“ACON“), introduced right now that ACON Latin America Alternatives Fund V, L.P. (the “Fund“) in partnership with a few of its Restricted Companions as co-investors, accomplished, on Could 27, 2021, the acquisitions of the businesses that type the Vitalis Group (“Vitalis“) a number one producer and wholesaler of generic injectable prescription drugs with manufacturing services in Colombia and Mexico, with gross sales to greater than 20 nations, primarily in Latin America. Vitalis is consultant of ACON’s Latin American funding technique during the last three a long time the place it’s now investing its fifth fund for the area.
ACON believes that Vitalis affords a novel platform to develop and cross-sell its greater than 700 pharmaceutical merchandise to a number of nations throughout Latin America. Vitalis’ merchandise comprise over 150 molecules in a number of therapeutic areas together with antibiotics, anesthetics, analgesics, and gastrointestinal.
The Restricted Companions of the Fund that invested in Vitalis as co-investors embrace DEG – Deutsche Investitions- und Entwicklungsgesellschaft mbH (“DEG“), Nederlandse Financierings-Maatschappij voor Ontwikkelingslanden N.V. (“FMO“) and Société de Promotion et de Participation pour la Coopération Économique S.A. (“Proparco“).
“Vitalis additional bolsters ACON’s technique of investing in medium-sized companies throughout a variety of industries which maintain essential aggressive positions and have vital publicity to hard-currency export markets. Moreover, this transaction builds on ACON’s expertise within the pharmaceutical business within the US and Latin America,” commented Alberto Hernandez, Associate of ACON.
As a part of the transaction, ACON recruited Esteban Lizarazo as CEO of Vitalis. Mr. Lizarazo has held a number of senior administration positions within the healthcare business in Colombia together with CEO of Grupo Amarey, a big distributor of prescription drugs and medical units to the institutional sector in Colombia.
Mr. Lizarazo commented, “Beneath the route of Vitalis’ founder and former CEO, Vitalis established itself as a dependable producer of high quality generic injectable prescription drugs in Colombia and Mexico and constructed the constructing blocks of a pan-regional distribution and gross sales community. I’m excited to hitch Vitalis and lead its subsequent part of progress throughout the area and past.”
José Miguel Knoell, Managing Associate of ACON, famous, “ACON’s acquisition of Vitalis demonstrates ACON’s means to supply and negotiate enticing investments in companies working throughout Latin America by leveraging our a long time lengthy expertise and funding groups throughout the area.” Mr. Knoell, added, “The Vitalis transaction represents the primary funding made out of ACON’s fifth pool of capital for Latin America, ACON Latin America Alternatives Fund V, L.P.”
Phrases of the transaction weren’t disclosed.
Brigard & Urrutia S.A.S. suggested Vitalis’ shareholders whereas Grant Thornton LLP, Winston & Strawn LLP, Gómez-Pinzón Abogados S.A.S., and Mijares, Angoitia, Cortés y Fuentes, S.C. suggested ACON.
About ACON Investments
ACON Investments, L.L.C. is a Washington, DC-based worldwide non-public fairness funding agency that manages non-public fairness funds and particular function partnerships that make investments in the US, Latin America and Europe. Based in 1996, ACON has accountability for managing roughly $6.0 billion of capital. ACON has professionals in Washington, DC, Los Angeles, Mexico Metropolis, São Paulo, Bogotá and Madrid. For extra data, go to www.aconinvestments.com.
ACON Investments, L.L.C.
SOURCE ACON Investments, L.L.C.